MARKET

TENX

TENX

Tenax Therapeut
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.010
-0.070
-3.37%
Opening 11:41 06/24 EDT
OPEN
1.990
PREV CLOSE
2.080
HIGH
2.070
LOW
1.980
VOLUME
120.47K
TURNOVER
--
52 WEEK HIGH
3.680
52 WEEK LOW
0.8037
MARKET CAP
50.65M
P/E (TTM)
-0.3854
1D
5D
1M
3M
1Y
5Y
45 Biggest Movers From Yesterday
Gainers Entera Bio Ltd. (NASDAQ: ENTX) shares surged 44.8% to close at $6.50 on Wednesday after the company reported topline Phase 2 bone mineral density data for EB613.
Benzinga · 6h ago
Healthcare names dominate premarket gainers
SeaChange International (SEAC) +26% on insider buying.ReTo Eco-Solutions (RETO) +21% after announcing new iron tailings project.Achieve Life Sciences (ACHV) +17%.Jiuzi Holdings, Inc. (JZXN) +15%.Tiziana Life Sciences PLC (TLSA) +11% on agreement with FHI
Seekingalpha · 1d ago
26 Stocks Moving in Wednesday's Pre-Market Session
Gainers Acasti Pharma Inc. (NASDAQ: ACST) rose 39% to $0.75 in pre-market trading after jumping 10% on Tuesday. The company reported a narrower FY21 loss.
Benzinga · 1d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers
Benzinga · 1d ago
Hedge Funds Are Selling Tenax Therapeutics Inc (TENX)
In this article we will analyze whether Tenax Therapeutics Inc (NASDAQ:TENX) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There’s no better way to get these firms’ immense res...
Insider Monkey · 06/14 20:25
Tenax therapeutics to join Russell Microcap
Tenax Therapeutics (TENX) to join the Russell Microcap Index at the conclusion of the 2021 Russell indexes annual reconstitution effect after the U.S. market opens on June 28.“Our inclusion in
Seekingalpha · 06/10 12:46
Tenax Therapeutics Set To Join Russell Microcap Index
Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need,
Benzinga · 06/10 12:42
BRIEF-Tenax Therapeutics Set To Join Russell Microcap® Index
reuters.com · 06/10 12:39
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TENX. Analyze the recent business situations of Tenax Therapeut through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TENX stock price target is 4.750 with a high estimate of 5.00 and a low estimate of 4.500.
EPS
Institutional Holdings
Institutions: 42
Institutional Holdings: 3.85M
% Owned: 25.70%
Shares Outstanding: 25.20M
TypeInstitutionsShares
Increased
4
464.75K
New
2
65.41K
Decreased
3
36.66K
Sold Out
3
74.68K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.62%
Pharmaceuticals & Medical Research
+1.10%
Key Executives
Chairman/Director
Gerald Proehl
President/Chief Financial Officer
Michael Jebsen
Chief Executive Officer/Director
Anthony DiTonno
Executive Vice President
Douglas Hay
Executive Vice President
Doug Randall
Other/Director
Stuart Rich
Other
Paula Bokesch
Director
I. Keith Maher
Director
June Almenoff
Director
Steven Boyd
Director
Michael Davidson
Director
Delcan Doogan
Director
Keith Maher
Director
James Mitchum
No Data
About TENX
Tenax Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing products for the critical care market. The Company's main product is levosimendan. Levosimendan is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure. Levosimendan represents therapeutic modalities for the treatment of Low Cardiac Output Syndrome (LCOS), septic shock and other critical care conditions. The therapeutic effects of levosimendan are mediated through increased cardiac contractility by calcium sensitization of troponin C, resulting in a positive inotropic effect, which is not associated with substantial increases in oxygen demand; opening of potassium channels in the vasculature smooth muscle, resulting in a vasodilatory effect on all vascular beds, and opening of mitochondrial potassium channels in cardiomyocytes, resulting in a cardioprotective effect.

Webull offers kinds of Tenax Therapeutics Inc stock information, including NASDAQ:TENX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TENX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TENX stock methods without spending real money on the virtual paper trading platform.